Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J., Randolph, S., Richon, V. M., Olsen, E. A. AMER SOC HEMATOLOGY. 2006: 122A

View details for Web of Science ID 000242440000400